Viatris

Viatris

Community score

+0.80 -55
SASB Industry: Biotechnology & Pharmaceuticals
Listing country: United States
Year added: 2018

Viatris emerged in November 2020 from the merger of Mylan N.V. and the Upjohn division of Pfizer, with its global headquarters situated in Canonsburg, Pennsylvania, United States. The company's operations span across several business segments which include Generic Drugs, offering an extensive array of generic pharmaceuticals such as tablets, capsules, injectables, and inhalants. Another segment covers Complex Generics and Biosimilars, featuring advanced generic drugs, like complex injectables, and biosimilars which are akin to original biologic drugs. Additionally, Viatris is involved in the marketing and selling of Branded Drugs in select therapeutic areas as well as providing Over-the-Counter (OTC) Medications that range from prescriptions to products for everyday consumer use. Among its portfolio, Viatris houses well-known brands like Lipitor® (atorvastatin), Norvasc® (amlodipine), Lyrica® (pregabalin), Viagra® (sildenafil citrate), and EpiPen® (epinephrine). The company's global reach extends to numerous countries, having a considerable market presence in regions including the United States, Europe, the Middle East, Asia, and Australia. (Powered by AI)

Show Company Information
You view a limited profile page without scores and metrics availability. Subscribing users get to see more advanced data, want to see it in action? Click on a company you are interested in: .
List View

Most negative / positive SDG

+2.50
-3.34